What is the P/E ratio for Moderna, Inc. (MRNA)?

The P/E ratio for MRNA stock is N/A.

What is the TTM average P/E ratio for Moderna, Inc. (MRNA)?

The TTM average P/E ratio for MRNA stock is 15.46.

Moderna, Inc. (MRNA)

Compare

Moderna, Inc. (MRNA) PE Ratio: N/A

The P/E ratio for Moderna, Inc. (MRNA) is N/A as of Wednesday, June 17, 2026.

PEG Ratio|P/B Ratio|EPS|All Metrics

MRNA PE Ratio Chart

MRNA PE Ratio

26.09+475.94% 1Y

Zoom

MRNA Average PE Ratio Chart

MRNA PE Ratio Metrics

PE RATIO

N/A

PE RATIO AVG TTM

15.46

PE RATIO AVG 3Y

N/A

PE RATIO AVG 5Y

N/A

PE RATIO AVG 10Y

N/A

PE RATIO AVG 15Y

N/A

PE RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

MRNA Competitors' PE Ratio

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Moderna, Inc. (MRNA)	$21.98B	N/A	15.46	N/A	N/A
Labcorp Holdings Inc. (LH)vs ›	$21.71B	23.45	27.14	32.20	23.42
BioNTech SE (BNTX)vs ›	$23.27B	N/A	55.73	22.62	82.47
Mettler-Toledo International Inc. (MTD)vs ›	$23.27B	26.96	31.95	32.76	36.37
United Therapeutics Corporation (UTHR)vs ›	$23.41B	20.39	17.18	14.95	16.04
Waters Corporation (WAT)vs ›	$23.53B	45.81	32.14	31.04	30.46
Veeva Systems Inc. (VEEV)vs ›	$25.96B	29.12	46.60	54.48	66.57
Hologic, Inc. (HOLX)vs ›	$16.97B	31.67	28.12	30.08	22.83
DexCom, Inc. (DXCM)vs ›	$28.23B	31.26	41.52	70.74	113.24
Biogen Inc. (BIIB)vs ›	$28.88B	20.94	16.65	18.54	18.66

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$55.40

Forward EPS (Est.)

$-4.72

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

Moderna, Inc. PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Moderna, Inc. PE Ratio FAQ

What is the P/E ratio for Moderna, Inc. (MRNA)?: The P/E ratio for MRNA stock is N/A.
What is the TTM average P/E ratio for Moderna, Inc. (MRNA)?: The TTM average P/E ratio for MRNA stock is 15.46.

Moderna, Inc. PE Ratio History

DATE	PE RATIO
2023-11-02	26.09
2023-11-01	27.91
2023-10-31	27.82
2023-10-30	27.13
2023-10-27	26.34
2023-10-26	27.83
2023-10-25	28.12
2023-10-24	29.22
2023-10-23	28.81
2023-10-20	29.45
2023-10-19	30.17
2023-10-18	31.51
2023-10-17	31.62
2023-10-16	33.68
2023-10-13	36.01
2023-10-12	36.92
2023-10-11	37.64
2023-10-10	38.25
2023-10-09	37.30
2023-10-06	38.05
2023-10-05	37.72
2023-10-04	38.19
2023-10-03	37.76
2023-10-02	37.84
2023-09-29	37.84
2023-09-28	36.73
2023-09-27	36.42
2023-09-26	35.94
2023-09-25	35.96
2023-09-22	36.63
2023-09-21	36.71
2023-09-20	37.92
2023-09-19	39.10
2023-09-18	38.15
2023-09-15	41.97
2023-09-14	41.32
2023-09-13	39.78
2023-09-12	38.55
2023-09-11	38.75
2023-09-08	39.43
2023-09-07	39.69
2023-09-06	39.65
2023-09-05	40.06
2023-09-01	41.23
2023-08-31	41.42
2023-08-30	42.72
2023-08-29	42.49
2023-08-28	41.70
2023-08-25	41.00
2023-08-24	41.26
2023-08-23	42.29
2023-08-22	42.58
2023-08-21	40.69
2023-08-18	37.22
2023-08-17	38.92
2023-08-16	36.23
2023-08-15	35.32
2023-08-14	36.63
2023-08-11	37.18
2023-08-10	36.73
2023-08-09	37.30
2023-08-08	36.53
2023-08-07	37.07
2023-08-04	39.63
2023-08-03	40.27
2023-08-02	9.51
2023-08-01	9.83
2023-07-31	10.15
2023-07-28	10.24
2023-07-27	10.23
2023-07-26	10.41
2023-07-25	10.52
2023-07-24	10.61
2023-07-21	10.91
2023-07-20	10.77
2023-07-19	10.80
2023-07-18	10.58
2023-07-17	10.58
2023-07-14	10.47
2023-07-13	10.92
2023-07-12	10.86
2023-07-11	10.54
2023-07-10	10.62
2023-07-07	10.26
2023-07-06	10.21
2023-07-05	10.66
2023-07-03	10.50
2023-06-30	10.48
2023-06-29	10.54
2023-06-28	10.61
2023-06-27	10.41
2023-06-26	10.39
2023-06-23	10.22
2023-06-22	10.40
2023-06-21	10.45
2023-06-20	10.72
2023-06-16	11.11
2023-06-15	11.21
2023-06-14	10.88
2023-06-13	11.04
2023-06-12	10.66
2023-06-09	10.64
2023-06-08	10.78
2023-06-07	10.84
2023-06-06	10.95
2023-06-05	11.12
2023-06-02	11.26
2023-06-01	11.09
2023-05-31	11.02
2023-05-30	10.86
2023-05-26	10.89
2023-05-25	10.91
2023-05-24	11.35
2023-05-23	11.89
2023-05-22	10.94
2023-05-19	10.89
2023-05-18	10.81
2023-05-17	10.83
2023-05-16	10.79
2023-05-15	11.24
2023-05-12	11.16
2023-05-11	11.08
2023-05-10	11.29
2023-05-09	11.54
2023-05-08	11.37
2023-05-05	11.82
2023-05-04	11.59
2023-05-03	6.52
2023-05-02	6.58
2023-05-01	6.68
2023-04-28	6.65
2023-04-27	6.51
2023-04-26	6.55
2023-04-25	6.76
2023-04-24	6.92
2023-04-21	7.05
2023-04-20	7.07
2023-04-19	7.15
2023-04-18	7.14
2023-04-17	7.21
2023-04-14	7.87
2023-04-13	8.04
2023-04-12	7.79
2023-04-11	7.77
2023-04-10	8.02
2023-04-06	7.93
2023-04-05	7.74
2023-04-04	7.84
2023-04-03	7.99
2023-03-31	7.69
2023-03-30	7.38
2023-03-29	7.45
2023-03-28	7.36
2023-03-27	7.43
2023-03-24	7.56
2023-03-23	7.48
2023-03-22	7.42
2023-03-21	7.62
2023-03-20	7.74
2023-03-17	7.51
2023-03-16	7.60
2023-03-15	7.49
2023-03-14	7.58
2023-03-13	7.41
2023-03-10	6.92
2023-03-09	6.88
2023-03-08	7.11
2023-03-07	7.06
2023-03-06	7.21
2023-03-03	7.17
2023-03-02	6.90
2023-03-01	6.79
2023-02-28	6.95
2023-02-27	6.92
2023-02-24	6.97
2023-02-23	5.34
2023-02-22	5.72
2023-02-21	5.79
2023-02-17	6.03
2023-02-16	6.23
2023-02-15	6.41
2023-02-14	6.35
2023-02-13	6.20
2023-02-10	6.12
2023-02-09	5.95
2023-02-08	5.95
2023-02-07	6.19
2023-02-06	6.16
2023-02-03	6.27
2023-02-02	6.38
2023-02-01	6.31
2023-01-31	6.37
2023-01-30	6.54
2023-01-27	6.85
2023-01-26	6.99
2023-01-25	6.99
2023-01-24	7.12
2023-01-23	7.13
2023-01-20	7.02
2023-01-19	6.89
2023-01-18	7.13
2023-01-17	6.90
2023-01-13	6.95
2023-01-12	6.80
2023-01-11	6.75
2023-01-10	6.86
2023-01-09	6.66
2023-01-06	6.52
2023-01-05	6.28
2023-01-04	6.42
2023-01-03	6.48
2022-12-30	6.50
2022-12-29	6.47
2022-12-28	6.39
2022-12-27	6.52
2022-12-23	7.20
2022-12-22	7.54
2022-12-21	7.60
2022-12-20	7.28
2022-12-19	6.87
2022-12-16	6.99
2022-12-15	7.50
2022-12-14	7.56
2022-12-13	7.15
2022-12-12	5.97
2022-12-09	6.42
2022-12-08	6.68
2022-12-07	6.48
2022-12-06	6.28
2022-12-05	6.37
2022-12-02	6.60
2022-12-01	6.57
2022-11-30	6.36
2022-11-29	6.26
2022-11-28	6.35
2022-11-25	6.38
2022-11-23	6.40
2022-11-22	6.50
2022-11-21	6.39
2022-11-18	6.57
2022-11-17	6.65
2022-11-16	6.70
2022-11-15	6.71
2022-11-14	6.48
2022-11-11	6.19
2022-11-10	6.10
2022-11-09	5.90
2022-11-08	5.96
2022-11-07	5.93
2022-11-04	5.73
2022-11-03	5.34
2022-11-02	4.53
2022-11-01	4.71
2022-10-31	4.58
2022-10-28	4.60
2022-10-27	4.39
2022-10-26	4.33
2022-10-25	4.16
2022-10-24	4.05
2022-10-21	3.91

Showing the most recent 260 of 629 data points. The chart above shows the full history.

Related Metrics

PEG Ratio P/B Ratio EPS All Metrics

See the Lowest P/E Ratio Stocks ranking →

About Moderna, Inc.

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

Cambridge, MA

5,800 employees

www.modernatx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Stéphane Bancel

View full financials